Table 5.

Comparison of assay performances of commercial and in-house ELISAs.

			Seropositivity by in-house ELISA
			RBD-IgG ELISA	RBD-IgM ELISA	NC-IgG ELISA	NC-IgM ELISA
Total study group			70.0% (n = 35/50)	84.0% (n = 42/50)	88.0% (n = 44/50)	82.0% (n = 41/50)
Commercial ELISA kits (RBD-IgG, RBD-IgM, NC-IgG, or NC-IgM)	Seropositives	48.0% (n = 24/50)	100.0% (n = 24/24)	100.0% (n = 24/24)	100.0% (n = 24/24)	95.8% (n = 23/24)
	Equivocal	28.0% (n = 14/50)	71.4% (n = 10/14)	92.9% (n = 13/14)	92.9% (n = 13/14)	85.7% (n = 12/14)
	Seronegatives	24.0% (n = 12/50)	8.3% (n = 1/12)	41.7% (n = 5/12)	58.3% (n = 7/12)	50.0% (n = 6/12)